Background
The long-term storage of umbilical cord blood (UCB) has gained traction and is increasingly regarded as a form of partial blood insurance. It involves the storage of blood present in the umbilical cord at birth and of tissue left over from the umbilical cord and placenta after birth. Such blood and tissue tend to contain pluripotent haematopoietic stem cells (HSCs). These can potentially be used to treat some serious blood and immune system diseases both in the donor (later in life) or in related or unrelated individuals (allogeneic transplantation). Otherwise, HSCs can be collected from the bone marrow (in an invasive procedure involving general anaesthesia) or from peripheral blood (in which case they are found in a much lower circulation).
Cord blood and placentae were historically discarded after birth and indeed in the absence of UCB banking they mostly still are disposed although of course certain cultural practices such as ingestion etc, are applied.
Cord blood can be stored long-term at the temperature range of the liquid phase of nitrogen, generally for up to 25 years - and thats what many private cord blood banking companies (BloodCos) encourage parents to do.
Public storage programmes have been available on a more limited scale since the 1990s, and the blood donated to them is usually controlled by the healthcare provider.
BloodCos promise the parents to retain control over the blood and use it for future treatment, generally of the donor or related family members. The number of BloodCos operating in Bulgaria is rising; 11 licensed private BloodCo offerings were marketed as at January 2020; approximately 20 980 bulgarian families have stored cord blood in BloodCos (*1) (compared to 7 licensed cord blood banks operating in the UK).
This leads to a lot of options to choose from and can be confusing. Parents are often persuaded to sign up by a desire to guarantee the future well-being of their children.
Giving blood and tissue for storage to a BloodCo is costly: a one-off fee between EUR 2,000.00 and EUR 3,500.00, with additional annual fees typically around EUR 100.00.
Given the importance and hope parents attach to the idea of protecting their childrens future health and the relatively large sums of money involved, families who decide to store blood and tissue in a BloodCo must consider how protected their investment is and in what ways are they entitled to control the stored material.
Legal grounds to store blood and tissue from the umbilical cord and placenta
Bulgarian legislation
Pursuant to s. 28 of the Bulgarian Organ, Tissue and Cell Transplantation Act, to be able to store cord blood and tissue legally, a BloodCo must receive informed consent from the childs mother. The consent of the biological or future legal father (if known) is neither sufficient nor required.
However, once whole blood from the placenta is collected, there may be no objection for other parties to enter into a contractual agreement concerning the now removed blood. At this stage, another parent (e.g., the father) or perhaps another relative (e.g., a grandparent) could become a contractual party in relation to a contract dealing with the storage and disposal of cord blood.
Parents often themselves approach a BloodCo in advance of an expected birth and enter into a cord blood storage agreement (often labelled Stem Cells Storage Agreement) (Storage Agreement) which contains the mothers informed consent to the storage. This allows the BloodCo to lawfully extract blood from the umbilical cord and placenta when the baby is born and store it.
Storage Agreement To achieve its advertised or assumed purpose, the Storage Agreement must guarantee that the donor child (when adult) and possibly the parents will be able to use stored material and will have control over it at their discretion within the law.
Example clauses
Control Rights
The Storage Agreement must set out clearly who can control the stored material containing the UCB. This needs to include the right to deal with all or some of the stored material by for example providing it to a treatment provider to develop a treatment; making it available for research; discarding it; requiring its removal or handover (including to other BloodCo). Where appropriate, it ought to detail who has ownership rights over the material. It ought to be clear whether these rights exclusively belong to the
Right to remove and hand over
Given that the Bulgarian market for UCB is small, it may not be able to sustain as many BloodCos purely domestically as are currently offering their service. Mothers giving birth in Bulgaria may then use cross-border providers, typically from elsewhere in the EU. These providers are more likely to have the scale to survive in the market but may either operate facilities in Bulgaria permanently or only intermittently with enough facilities to collect and possibly store but with bigger or more important parts of their business being located elsewhere.
The right to require relocation of the material is therefore especially relevant to a small market such as Bulgaria. Recently, one of the BloodCos, incorporated in Switzerland and operating in Bulgaria, was declared insolvent.
This provoked a lot of questions and confusion about what will happen with the stored material and where it will be relocated, respectively stored. This confusion can be limited if on entering into a Storage Agreement, a parent demands a clause which expressly allows them to relocate the stored material at their discretion.
Provisions by the BloodCo
It is highly advisable that the Storage Agreement contains express provisions on use of the stored UCB. Key protections concern:
For example, one of BloodCo operating in Bulgaria provides that in case of its insolvency, storage will be taken over by a separate independent company. This still needs to be investigated (e.g. is the second BloodCo truly separate or may it be threatened by the insolvency or financial difficulties of the first company). This can be done by the parents or, if they decide, by an experienced lawyer.
Conclusion
The storage of blood and tissue left over in the umbilical cord and placenta is a common occurrence and typically governed by a contractual agreement. Before entering into a Storage Agreement parents should be aware of the risks which arise.
Since the decision to bank cord blood is a form of insurance (i.e., it is intended to deal with a future risk), it is important to make sure that at least basic steps are taken that the agreement is effective. At the same time, in the case of cord blood, these can be dealt with purely contractually, with interesting questions of cross-border insolvency and title also arising.
If parents want the Storage Agreement to serve them well, they must make an informed decision on its terms which also probably requires legal analysis.
See the article here:
Cord blood banking in Bulgaria: problems of control and continuing insurance - Lexology
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
- The neonatal southern white rhinoceros ovary contains oogonia in ... - Nature.com - October 18th, 2023
- OMG: Sperm injury led to rare baby struggle - news.com.au - October 18th, 2023
- Experts Explain how MS Impacts the Eyes and Eye Health - Health Central - October 18th, 2023
- Newly identified stem cells can lure breast cancer to the spine - Science News Magazine - October 15th, 2023
- Cases of HIV cure | aidsmap - aidsmap - October 15th, 2023
- HokUS-10 scoring system predicts the treatment outcome for ... - Nature.com - October 13th, 2023
Recent Comments